Ruby Leong
YOU?
Author Swipe
View article: Supplementary Table S2 from FDA Approval Summary: Abatacept for the Prophylaxis of Acute GVHD
Supplementary Table S2 from FDA Approval Summary: Abatacept for the Prophylaxis of Acute GVHD Open
Key demographic, disease, and other characteristics at transplant for the weighted samples using stabilized inverse probability of treatment weighting with propensity scores – IM101841
View article: Supplementary Table S1 from FDA Approval Summary: Abatacept for the Prophylaxis of Acute GVHD
Supplementary Table S1 from FDA Approval Summary: Abatacept for the Prophylaxis of Acute GVHD Open
Rationale for Dosage Selection of Abatacept for Prophylaxis of aGVHD
View article: Supplementary Table S4 from FDA Approval Summary: Abatacept for the Prophylaxis of Acute GVHD
Supplementary Table S4 from FDA Approval Summary: Abatacept for the Prophylaxis of Acute GVHD Open
Study 101841 Observational Study Select Limitations
View article: Supplementary Table S3 from FDA Approval Summary: Abatacept for the Prophylaxis of Acute GVHD
Supplementary Table S3 from FDA Approval Summary: Abatacept for the Prophylaxis of Acute GVHD Open
Study IM101841: Overall survival results at Day 180 Post-Transplantation Using Stabilized Inverse Probability of Treatment Weighting with Propensity Scores
View article: Data from FDA Approval Summary: Abatacept for the Prophylaxis of Acute GVHD
Data from FDA Approval Summary: Abatacept for the Prophylaxis of Acute GVHD Open
In December 2021, the FDA approved abatacept (Orencia; Bristol Myers Squibb) in combination with a calcineurin inhibitor (CNI) and methotrexate (MTX) as the first drug for the prophylaxis of acute GVHD (aGVHD) in adult and pediatric (2 yea…
View article: Utility of Physiologically Based Pharmacokinetic Modeling to Investigate the Impact of Physiological Changes of Pregnancy and Cancer on Oncology Drug Pharmacokinetics
Utility of Physiologically Based Pharmacokinetic Modeling to Investigate the Impact of Physiological Changes of Pregnancy and Cancer on Oncology Drug Pharmacokinetics Open
Background: The treatment of cancer during pregnancy remains challenging with knowledge gaps in drug dosage, safety, and efficacy due to the under-representation of this population in clinical trials. Our aim was to investigate physiologic…
View article: FDA Approval Summary: Pirtobrutinib for Relapsed or Refractory Mantle Cell Lymphoma
FDA Approval Summary: Pirtobrutinib for Relapsed or Refractory Mantle Cell Lymphoma Open
In January 2023, the FDA granted accelerated approval to pirtobrutinib for the treatment of adult patients with relapsed or refractory mantle cell lymphoma (MCL) after at least two lines of systemic therapy, including a Bruton tyrosine kin…